Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
暂无分享,去创建一个
[1] K. Laake,et al. Thrombocytes and treatment with heparin from porcine mucosa. , 2009, Scandinavian journal of haematology. Supplementum.
[2] J. Kelton,et al. Quantitative interpretation of optical density measurements using PF4‐dependent enzyme‐immunoassays , 2008, Journal of thrombosis and haemostasis : JTH.
[3] L. Rice,et al. Argatroban therapy in heparin-induced thrombocytopenia , 2008, Expert review of clinical pharmacology.
[4] D. Ganzer,et al. Thromboembolieprophylaxe als Auslöser thrombembolischer Komplikationen , 2008 .
[5] T. Warkentin,et al. The Approach to Heparin-Induced Thrombocytopenia , 2008, Seminars in respiratory and critical care medicine.
[6] C. Sigouin,et al. What is the potential for overdiagnosis of heparin‐induced thrombocytopenia? , 2007, American journal of hematology.
[7] A. Gamst,et al. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis. , 2007, Chest.
[8] A. Gray,et al. Argatroban Therapy for Heparin-Induced Thrombocytopenia in Acutely Ill Patients , 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[9] N. Smedira,et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. , 2007, The Annals of thoracic surgery.
[10] I. Jang,et al. Argatroban Therapy in Patients with Coronary Artery Disease and Heparin-Induced Thrombocytopenia , 2007, Cardiology.
[11] A. Greinacher,et al. Heparin‐induced thrombocytopenia: a prospective study on the incidence, platelet‐activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes , 2007, Journal of thrombosis and haemostasis : JTH.
[12] L. Rice,et al. Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin‐induced Thrombocytopenia , 2007, Journal of clinical pharmacology.
[13] R. Aster,et al. Heparin-induced thrombocytopenia associated with fondaparinux. , 2007, The New England journal of medicine.
[14] J. Mattson,et al. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. , 2007, Chest.
[15] J. Bradner,et al. Emerging Anticoagulants and Heparin-Induced Thrombocytopenia: Indirect and Direct Factor Xa Inhibitors and Oral Thrombin Inhibitors , 2007 .
[16] A. Koster,et al. Management of Intraoperative Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiovascular Surgery , 2007 .
[17] R. Hetzer,et al. Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. , 2007, The Journal of thoracic and cardiovascular surgery.
[18] J. Peters,et al. Argatroban Anticoagulation in Critically III Patients , 2007, The Annals of pharmacotherapy.
[19] E. Lindhoff-Last,et al. Danaparoid in der Schwangerschaft bei Heparinunverträglichkeit , 2007, Hämostaseologie.
[20] N. Smedira,et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. , 2007, The Annals of thoracic surgery.
[21] G. Kloecker,et al. Argatroban for anticoagulation during cardiac surgery , 2006, European journal of haematology.
[22] R. Rosovsky,et al. The Incidence of Thrombosis in Patients with Isolated Heparin Induced Thrombocytopenia. , 2006 .
[23] D. McCollum,et al. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia , 2006, Journal of Thrombosis and Thrombolysis.
[24] T. Kohlmann,et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. , 2006, Blood.
[25] R. Pendleton,et al. Incidence and Economic Implications of Heparin‐Induced Thrombocytopenia in Medical Patients Receiving Prophylaxis for Venous Thromboembolism , 2006, Pharmacotherapy.
[26] T. Warkentin,et al. Testing for heparin-induced thrombocytopenia antibodies. , 2006, Transfusion medicine reviews.
[27] P. Morange,et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. , 2006, Blood.
[28] R. Hetzer,et al. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. , 2006, The Journal of thoracic and cardiovascular surgery.
[29] F. Spertini,et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. , 2006, Blood.
[30] N. Smedira,et al. Bivalirudin Provides Rapid, Effective, and Reliable Anticoagulation During Off-Pump Coronary Revascularization: Results of the “EVOLUTION OFF” Trial , 2006, Anesthesia and analgesia.
[31] T. Ortel,et al. Heparin-induced thrombocytopenia. , 2006, Seminars in hematology.
[32] L. Efird,et al. Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia , 2006, The Annals of pharmacotherapy.
[33] R. Lange,et al. Use of heparin upon reoperation in a pediatric patient with heparin-induced thrombocytopenia after disappearance of antibodies , 2006, Clinical Research in Cardiology.
[34] J. Kirklin,et al. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[35] R. Levine,et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. , 2006, Chest.
[36] M. Morshuis,et al. Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support. , 2006, The Journal of thoracic and cardiovascular surgery.
[37] H. Magnani,et al. Heparin-induced thrombocytopenia (HIT) , 2006, Thrombosis and Haemostasis.
[38] A. Greinacher,et al. Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia , 2006, European journal of haematology.
[39] R. Levine,et al. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. , 2006, Chest.
[40] T. Warkentin. Should vitamin K be administered when HIT is diagnosed after administration of coumarin? , 2006, Journal of thrombosis and haemostasis : JTH.
[41] V. Durkalski,et al. Evaluation of Treatment with Direct Thrombin Inhibitors in Patients with Heparin‐Induced Thrombocytopenia , 2006, Pharmacotherapy.
[42] T. Kiser,et al. Evaluation of Bivalirudin Treatment for Heparin‐Induced Thrombocytopenia in Critically Ill Patients with Hepatic and/or Renal Dysfunction , 2006, Pharmacotherapy.
[43] C. Sigouin,et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings , 2006, Journal of thrombosis and haemostasis : JTH.
[44] N. Smedira,et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. , 2006, Journal of Thoracic and Cardiovascular Surgery.
[45] N. Smedira,et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. , 2006, The Journal of thoracic and cardiovascular surgery.
[46] L. Rice,et al. Argatroban for Suspected Heparin-Induced Thrombocytopenia: Contemporary Experience at a Large Teaching Hospital , 2006, Journal of intensive care medicine.
[47] T. Warkentin,et al. No significant improvement in diagnostic specificity of an anti‐PF4/polyanion immunoassay with use of high heparin confirmatory procedure , 2006, Journal of thrombosis and haemostasis : JTH.
[48] G. Clagett,et al. Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis After Intraoperative Heparin Anticoagulation , 2006, Vascular and endovascular surgery.
[49] P. Murray,et al. Heparin-Induced Thrombocytopenia in Patients Administered Heparin Solely for Hemodialysis , 2006, Renal failure.
[50] R. Arnold,et al. The Cost-Effectiveness of Argatroban Treatment in Heparin-Induced Thrombocytopenia: The Effect of Early Versus Delayed Treatment , 2006, Cardiology in review.
[51] R. Aghababian,et al. Heparin‐induced thrombocytopenia from venous thromboembolism treatment , 2005, Journal of internal medicine.
[52] Y. Gruel,et al. Development of antibodies specific to polyanion‐modified platelet factor 4 during treatment with fondaparinux , 2005, Journal of thrombosis and haemostasis : JTH.
[53] R. MacLaren,et al. Evaluation of Diagnostic Tests and Argatroban or Lepirudin Therapy in Patients with Suspected Heparin‐Induced Thrombocytopenia , 2005, Pharmacotherapy.
[54] J. Kelton,et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? , 2005, The Journal of laboratory and clinical medicine.
[55] B. Eriksson,et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. , 2005, Blood.
[56] P. Prandoni,et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. , 2005, Blood.
[57] A. Greinacher,et al. Lepirudin in patients with heparin‐induced thrombocytopenia – results of the third prospective study (HAT‐3) and a combined analysis of HAT‐1, HAT‐2, and HAT‐3 , 2005, Journal of thrombosis and haemostasis : JTH.
[58] A. Greinacher,et al. Unfractionated LMWH and the risk of HIT: are medical patients different? , 2005 .
[59] T. Lecompte,et al. Lepirudin: is the approved dosing schedule too high? , 2005, Journal of thrombosis and haemostasis : JTH.
[60] A. Greinacher,et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation , 2005, Thrombosis and Haemostasis.
[61] A. Greinacher,et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. , 2005, Blood.
[62] P. Wells,et al. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. , 2005, Blood.
[63] H. Messmore,et al. IN FOCUS: Activation of platelets by heparin‐induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin , 2005, Journal of thrombosis and haemostasis : JTH.
[64] J. Mattson,et al. A Comparison of Lepirudin and Argatroban Outcomes , 2005, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[65] E. Grossman,et al. Argatroban Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Requiring Renal Replacement Therapy , 2005, The Annals of pharmacotherapy.
[66] M. Kovacs,et al. Fondaparinux: A potential new therapy for HIT , 2005, Hematology.
[67] I. Greer,et al. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. , 2005, Blood.
[68] A. Koster,et al. Bivalirudin: a review , 2005, Expert opinion on pharmacotherapy.
[69] B. Lewis,et al. Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia , 2005, Clinical and applied thrombosis/hemostasis.
[70] T. Kohlmann,et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis , 2005, Thrombosis and Haemostasis.
[71] N. Smedira,et al. Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study. , 2005, The Journal of thoracic and cardiovascular surgery.
[72] J. Bartholomew,et al. Transitioning from Argatroban to Warfarin in Heparin-Induced Thrombocytopenia: An Analysis of Outcomes in Patients with Elevated International Normalized Ratio (INR) , 2005, Journal of Thrombosis and Thrombolysis.
[73] J. Hirsh,et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. , 2005, Chest.
[74] T. Klockgether,et al. Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin , 2005, Neurology.
[75] Gustavo A. Cardenas,et al. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. , 2005, Mayo Clinic proceedings.
[76] J. Mattson,et al. Delayed-Onset Heparin-Induced Thrombocytopenia , 2005, Annals of Internal Medicine.
[77] Y. Gruel,et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin‐dependent antibodies , 2005, British journal of haematology.
[78] J. Zwicker,et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin‐induced thrombocytopenia , 2004, Journal of thrombosis and haemostasis : JTH.
[79] Naadede Badger,et al. Excessive Anticoagulation and Anaphylactic Reaction After Rechallenge with Lepirudin in a Patient with Heparin‐Induced Thrombocytopenia , 2004, Pharmacotherapy.
[80] Inder Singh,et al. Argatroban Dosage in Critically Ill Patients with HIT. , 2004 .
[81] A. Greinacher,et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. , 2004, Blood.
[82] H. Magnani,et al. Treatment of 51 pregnancies with danaparoid because of heparin intolerance , 2004, Thrombosis and Haemostasis.
[83] R. Levine,et al. Heparin-induced thrombocytopenia in the emergency department. , 2004, Annals of emergency medicine.
[84] P. Boutouyrie,et al. Diagnostic score for heparin‐induced thrombocytopenia after cardiopulmonary bypass , 2004, Journal of thrombosis and haemostasis : JTH.
[85] A. Koster,et al. Extracorporeal Elimination of Large Concentrations of Tirofiban by Zero-Balanced Ultrafiltration During Cardiopulmonary Bypass: An In Vitro Investigation , 2004, Anesthesia and analgesia.
[86] A. Golichowski,et al. Treatment of heparin induced thrombocytopenia and thrombosis during the first trimester of pregnancy , 2004, Journal of thrombosis and haemostasis : JTH.
[87] G. Raskob,et al. Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis , 2004, Annals of Internal Medicine.
[88] C. Kitchens. Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin‐induced thrombocytopenia , 2004, American journal of hematology.
[89] M. LaMonte,et al. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy , 2004, Critical care medicine.
[90] T. Warkentin. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. , 2004, Best practice & research. Clinical haematology.
[91] A. Merry,et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. , 2004, The Annals of thoracic surgery.
[92] N. Smedira,et al. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. , 2004, The American journal of cardiology.
[93] A. Greinacher,et al. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. , 2004, Blood.
[94] J. Bartholomew,et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. , 2004, Archives of internal medicine.
[95] R. Whitlock,et al. Warfarin‐associated multiple digital necrosis complicating heparin‐induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma‐associated thrombotic endocarditis , 2004, American journal of hematology.
[96] R. Hallisey,et al. Effect of Renal Function on the Pharmacodynamics of Argatroban , 2004, The Annals of pharmacotherapy.
[97] K. Fischer. Hemodialysis in Heparin-Induced Thrombocytopenia , 2003 .
[98] J. Bartholomew. Bivalirudin for the Treatment of Heparin-Induced Thrombocytopenia , 2003 .
[99] A. Greinacher. Lepirudin for the Treatment of Heparin-Induced Thrombocytopenia , 2003 .
[100] T. Warkentin. Pseudo–Heparin-Induced Thrombocytopenia , 2003 .
[101] A. Greinacher,et al. Treatment of Heparin-Induced Thrombocytopenia: An Overview , 2003 .
[102] B. Poetzsch,et al. Management of Cardiopulmonary Bypass Anticoagulation in Patients with Heparin-Induced Thrombocytopenia , 2003 .
[103] B. Chong,et al. Danaparoid for the Treatment of Heparin-Induced Thrombocytopenia , 2003 .
[104] T. Warkentin,et al. Frequency of Heparin-Induced Thrombocytopenia , 2003 .
[105] J. Hirsh,et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. , 2003, Archives of internal medicine.
[106] B. Lewis,et al. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia. , 2003, The Journal of invasive cardiology.
[107] R. Califf,et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. , 2003, The Journal of invasive cardiology.
[108] M Gent,et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.
[109] A. Greinacher,et al. Anaphylactic and Anaphylactoid Reactions Associated With Lepirudin in Patients With Heparin-Induced Thrombocytopenia , 2003, Circulation.
[110] S. de Denus,et al. Decreased Argatroban Clearance Unaffected by Hemodialysis in Anasarca , 2003, The Annals of pharmacotherapy.
[111] J. Kelton,et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. , 2003, Archives of internal medicine.
[112] L. Rice,et al. Danaparoid for heparin‐induced thrombocytopenia: an analysis of treatment failures , 2003, European journal of haematology.
[113] A. Greinacher,et al. Heparin-induced thrombocytopenia and cardiac surgery. , 2003, The Annals of thoracic surgery.
[114] J. Bott,et al. Bivalrudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia , 2003 .
[115] J. Strong,et al. Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction. , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[116] M. J. Hursting,et al. Argatroban Dosing in Patients with Heparin-Induced Thrombocytopenia , 2003, The Annals of pharmacotherapy.
[117] J. Kelton,et al. Frequency of Heparin‐Induced Thrombocytopenia in Critical Care Patients , 2003, Pharmacotherapy.
[118] T. Warkentin,et al. Heparin‐induced thrombocytopenia: pathogenesis and management , 2003, British journal of haematology.
[119] T. Warkentin. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. , 2003, Thrombosis research.
[120] D. MacGregor,et al. Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia , 2003, The Annals of pharmacotherapy.
[121] P. Prandoni,et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. , 2003, Blood.
[122] D. Cook,et al. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. , 2003, Blood.
[123] W. Holman,et al. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. , 2003, Anesthesia and analgesia.
[124] B. Eriksson,et al. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. , 2003, Blood.
[125] R. Bernstein,et al. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. , 2003, The New England journal of medicine.
[126] N. Heddle,et al. Laboratory diagnosis of immune heparin-induced thrombocytopenia. , 2003, Current hematology reports.
[127] E. Topol,et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.
[128] G. Nuttall,et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. , 2003, Anesthesia and analgesia.
[129] A. Greinacher,et al. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. , 2003, The Annals of thoracic surgery.
[130] M. Carrier,et al. Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial. , 2003, The Journal of thoracic and cardiovascular surgery.
[131] A. Carter,et al. Gender differences in coagulation and fibrinolysis in white subjects with acute ischemic stroke , 2003, Journal of thrombosis and haemostasis : JTH.
[132] T. Ortel,et al. HEPARIN‐INDUCED THROMBOCYTOPENIA IN DIALYSIS: Alternative Methods of Anticoagulation for Dialysis‐dependent Patients with Heparin‐induced Thrombocytopenia , 2003 .
[133] F. Mertzlufft,et al. On the Prophylactic and Therapeutic Use of Danaparoid Sodium (Orgaran®) in Patients With Heparin-Induced Thrombocytopenia , 2003, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[134] D. Cohen,et al. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[135] F. Baciewicz,et al. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. , 2002, The Annals of thoracic surgery.
[136] T. Warkentin. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. , 2002, Archives of pathology & laboratory medicine.
[137] J. Moses,et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[138] P. Giangrande,et al. FONDAPARINUX (ARIXTRA®): A NEW ANTICOAGULANT , 2002, The Medical letter on drugs and therapeutics.
[139] D. Hoppensteadt,et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. , 2002, Thrombosis research.
[140] E. Lindhoff‐Last,et al. Heparin-Induced Thrombocytopenia-Alternative Anticoagulation in Pregnancy and Lactation , 2002, Seminars in thrombosis and hemostasis.
[141] B. Eriksson,et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.
[142] R. Apsner,et al. Long-term citrate anticoagulation for high-flux haemodialysis in a patient with heparin-induced thrombocytopenia type II. , 2002, Acta medica Austriaca.
[143] E. Lindhoff‐Last,et al. Incidence and clinical relevance of heparin‐induced antibodies in patients with deep vein thrombosis treated with unfractionated or low‐molecular‐weight heparin , 2002 .
[144] J. Mattson,et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin‐induced thrombocytopenia , 2002, American journal of hematology.
[145] A. Greinacher,et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. , 2002, Chest.
[146] C. Vergnes,et al. Absence of Placental Transfer of Pentasaccharide (Fondaparinux, Arixtra®) in the Dually Perfused Human Cotyledon in vitro , 2002, Thrombosis and Haemostasis.
[147] Y. Woo,et al. Danaparoid thromboprophylaxis in pregnant women with heparin‐induced thrombocytopenia , 2002, BJOG : an international journal of obstetrics and gynaecology.
[148] M. Poncz,et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. , 2002, Blood.
[149] J. Mattson,et al. Delayed-Onset Heparin-Induced Thrombocytopenia , 2002, Annals of Internal Medicine.
[150] R. Hetzer,et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. , 2001, The Journal of thoracic and cardiovascular surgery.
[151] A. Borel‐Derlon,et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies , 2001, BJOG : an international journal of obstetrics and gynaecology.
[152] T. Warkentin,et al. Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia. , 2001, The Annals of thoracic surgery.
[153] B. Chong,et al. Prospective Randomised Open-label Comparison of Danaparoid with Dextran 70 in the Treatment of Heparin-induced Thrombocytopaenia with Thrombosis , 2001, Thrombosis and Haemostasis.
[154] T. Warkentin. Venous Limb Gangrene during Warfarin Treatment of Cancer-Associated Deep Venous Thrombosis , 2001, Annals of Internal Medicine.
[155] J. Nelson,et al. Management of heparin allergy in pregnancy , 2001, American journal of hematology.
[156] C. Hogue,et al. The Relationship Between Hirudin and Activated Clotting Time: Implications for Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiac Surgery , 2001, Anesthesia and analgesia.
[157] R. Silver,et al. Heparin-induced thrombocytopenia is rare in pregnancy. , 2001, American journal of obstetrics and gynecology.
[158] A. Greinacher,et al. A Comparison of Danaparoid and Lepirudin in Heparin-induced Thrombocytopenia , 2001, Thrombosis and Haemostasis.
[159] R. Reilly,et al. A Case Review: Anticoagulation in Hemodialysis Patients with Heparin-Induced Thrombocytopenia , 2001, American Journal of Nephrology.
[160] J. Kelton,et al. Temporal aspects of heparin-induced thrombocytopenia. , 2001, The New England journal of medicine.
[161] J. Bartholomew,et al. Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia , 2001, Circulation.
[162] D. Sane,et al. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin‐induced thrombocytopenia undergoing percutaneous coronary intervention: Case reports , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[163] A. Greinacher,et al. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. , 2001, The Annals of thoracic surgery.
[164] D. Jorkasky,et al. Interpreting the International Normalized Ratio (INR) in Individuals Receiving Argatroban and Warfarin , 2001, Thrombosis and Haemostasis.
[165] R. Hetzer,et al. Anticoagulation during Cardiopulmonary Bypass in Patients with Heparin-induced Thrombocytopenia Type II and Renal Impairment Using Heparin and the Platelet Glycoprotein IIb–IIIa Antagonist Tirofiban , 2001, Anesthesiology.
[166] J. Lehot,et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. , 2001, The Annals of thoracic surgery.
[167] R. Califf,et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. , 2000, The Journal of invasive cardiology.
[168] R. Hetzer,et al. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant. , 2000, The Annals of thoracic surgery.
[169] T. Warkentin. Laboratory Testing for Heparin-Induced Thrombocytopenia , 2000, Journal of Thrombosis and Thrombolysis.
[170] A. Greinacher,et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. , 2000, Blood.
[171] P. Horsewood,et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia , 2000 .
[172] I. Greer,et al. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy , 2000, BJOG : an international journal of obstetrics and gynaecology.
[173] W. Klövekorn,et al. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. , 2000, The New England journal of medicine.
[174] V. Liebe,et al. A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study. , 2000, Thrombosis research.
[175] A. Greinacher,et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. , 2000, Blood.
[176] R. Hetzer,et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. , 2000, Journal of cardiothoracic and vascular anesthesia.
[177] A. Koster,et al. Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with on-line monitoring of platelet function. , 2000, Journal of cardiothoracic and vascular anesthesia.
[178] Y. Gruel,et al. Affinity purification of heparin‐dependent antibodies to platelet factor 4 developed in heparin‐induced thrombocytopenia: biological characteristics and effects on platelet activation , 2000, British journal of haematology.
[179] I. Vlachonikolis,et al. Aberrant expression of the major sialoglycoprotein (CD43) on the monocytes of patients with myelodysplastic syndromes , 2000, Annals of Hematology.
[180] H. Messmore,et al. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. , 1999, Chest.
[181] A. Cullinane,et al. Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices , 1999, Supportive Care in Cancer.
[182] M. Horne,et al. Heparin‐induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases , 1999, Journal of internal medicine.
[183] P. Fournel,et al. Lower Limb Veins Should be Systematically Explored in Patients with Isolated Heparin-induced Thrombocytopenia , 1999, Thrombosis and Haemostasis.
[184] W. Sikov,et al. Multicentric warfarin‐induced skin necrosis complicating heparin‐induced thrombocytopenia , 1999, American journal of hematology.
[185] U. Janssens,et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. , 1999, Circulation.
[186] P. Mismetti,et al. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. , 1999, Chest.
[187] J. Moran,et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. , 1999, The American journal of medicine.
[188] Y. Gruel,et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. , 1999, Circulation.
[189] B. Brenner,et al. Safety of Low-Molecular-Weight Heparin in Pregnancy: A Systematic Review , 1999, Thrombosis and Haemostasis.
[190] B. Strauss,et al. Combined use of orgaran and reopro during coronary angioplasty in patients unable to receive heparin , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[191] D. Gailani,et al. Anticoagulant‐induced skin necrosis in a patient with hereditary deficiency of protein S , 1999, American journal of hematology.
[192] U. Janssens,et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. , 1999, Circulation.
[193] J. Owen,et al. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. , 1998, Catheterization and cardiovascular diagnosis.
[194] T. Ortel,et al. Heparin-induced thrombocytopenia. , 1998, Annual review of medicine.
[195] T. Warkentin. Limitations of conventional treatment options for heparin-induced thrombocytopenia. , 1998, Seminars in hematology.
[196] R. Hetzer,et al. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. , 1998, Anesthesiology.
[197] M. Trossaërt,et al. High incidence of anti‐heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery , 1998, British journal of haematology.
[198] M. Contreras. The appropriate use of platelets: an update from the Edinburgh Consensus Conference. , 1998, British journal of haematology.
[199] M. Aiach,et al. Lack of sequence variations in the C4b‐BP β‐chain in patients with type III protein S deficiency bearing the Ser 460 to Pro mutation: description of two new intragenic isomorphisms in the C4b‐BP β‐chain gene (C4BPB) , 1998, British journal of haematology.
[200] R. Aster,et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. , 1998, Blood.
[201] B. Chong,et al. Heparin-induced Thrombocytopenia: Towards Consensus , 1998, Thrombosis and Haemostasis.
[202] P. Jagadeeswaran,et al. Effects of hirudin (thrombin specific inhibitor) in zebrafish embryos: a developmental role for thrombin. , 1997, Blood cells, molecules & diseases.
[203] P. Wille-Jørgensen,et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. , 1997, The New England journal of medicine.
[204] J. Kelton,et al. The Pathogenesis of Venous Limb Gangrene Associated with Heparin-Induced Thrombocytopenia , 1997, Annals of Internal Medicine.
[205] M. Kovacs,et al. SUCCESSFUL USE OF DANAPAROID IN TREATMENT OF HEPARIN‐INDUCED THROMBOCYTOPENIA DURING TWIN PREGNANCY , 1997, Obstetrics and gynecology.
[206] S. Nand,et al. Heparin‐induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution , 1997, American journal of hematology.
[207] K. Madlener,et al. Rekombinantes Hirudin als Antikoagulans für den kardiopulmonalen Bypass in der Herzchirurgie: Klinische Erfahrungen , 1997, Zeitschrift für Herz-, Thorax- und Gefäßchirurgie.
[208] H. Foda,et al. Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[209] J. Herbert,et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[210] J. Kelton,et al. A 14-year study of heparin-induced thrombocytopenia. , 1996, The American journal of medicine.
[211] T. Warkentin. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. , 1996, Transfusion medicine reviews.
[212] R. Aster,et al. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. , 1996, The Journal of laboratory and clinical medicine.
[213] J. Amiral,et al. Generation of antibodies to heparin‐PF4 complexes without thrombocytopenia in patients treated with unfractionated or low‐molecular‐weight heparin , 1996, American journal of hematology.
[214] T. Warkentin. Heparin‐induced skin lesions , 1996, British journal of haematology.
[215] H. Rupprecht,et al. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina. , 1995, Journal of the American College of Cardiology.
[216] L. Cohn,et al. Prevention of venous thrombosis after coronary artery bypass surgery (a randomized trial comparing two mechanical prophylaxis strategies). , 1995, The American journal of cardiology.
[217] M. Samama,et al. Absence of In Vitro Cross-Reaction of Pentasaccharide with the Plasma Heparin-Dependent Factor of Twenty-Five Patients with Heparin-Associated Thrombocytopenia , 1995, Thrombosis and Haemostasis.
[218] P. Serruys,et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. , 1995, The New England journal of medicine.
[219] A. Greinacher,et al. Characterization of the Structural Requirements for a Carbohydrate Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-associated Thrombocytopenia , 1995, Thrombosis and Haemostasis.
[220] D. Hoppensteadt,et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. , 1995, The Canadian journal of cardiology.
[221] J. Hirsh,et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.
[222] J. Fareed,et al. New Anticoagulants for the Cardiovascular Patient , 1995 .
[223] H. Magnani. Heparin-Induced Thrombocytopenia (HIT): An Overview of 230 Patients Treated with Orgaran (Org 10172) , 1993, Thrombosis and Haemostasis.
[224] A. J. Block,et al. Thrombocytopenia, cutaneous necrosis, and gangrene of the upper and lower extremities in a 35-year-old man. , 1992, Chest.
[225] P. Leyvraz,et al. Thromboembolic prophylaxis in total hip replacement: A comparison between the low molecular weight heparinoid Lomoparan and heparindihydroergotamine , 1992, The British journal of surgery.
[226] J. Amiral,et al. Platelet Factor 4 Complexed to Heparin Is the Target for Antibodies Generated in Heparin-Induced Thrombocytopenia , 1992, Thrombosis and Haemostasis.
[227] A. Greinacher,et al. Heparin-Associated Thrombocytopenia: The Antibody Is Not Heparin Specific , 1992, Thrombosis and Haemostasis.
[228] H. Büller,et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. , 1991, BMJ.
[229] G. Louridas. Heparin-induced thrombocytopenia. , 1991, South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie.
[230] T. Gerhart,et al. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial. , 1991, The Journal of bone and joint surgery. American volume.
[231] A. P. Ball,et al. Low incidence of thrombocytopenia with porcine mucosal heparin. A prospective multicenter study. , 1989, Archives of internal medicine.
[232] M. Sobel,et al. Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism. , 1988, Journal of vascular surgery.
[233] F. Markwardt,et al. Pharmacological survey of recombinant hirudin. , 1988, Die Pharmazie.
[234] B. Calhoun,et al. Heparin-associated antibody with pregnancy: discussion of two cases. , 1987, American journal of obstetrics and gynecology.
[235] D. Oscier,et al. HEPARIN‐INDUCED THROMBOCYTOPENIA IN PREGNANCY , 1987, British journal of haematology.
[236] H. Ayalon,et al. Heparin-induced thrombocytopenia and recurrent thrombosis in pregnancy. A case report. , 1986, The Journal of reproductive medicine.
[237] R. T. Bailey,et al. Heparin-Associated Thrombocytopenia: A Prospective Comparison of Bovine Lung Heparin, Manufactured by a New Process, and Porcine Intestinal Heparin , 1986, Drug intelligence & clinical pharmacy.
[238] C. Compton,et al. Fatal Reactions Associated with Intravenous Heparin , 1986, Drug intelligence & clinical pharmacy.
[239] Battey Pm,et al. Venous gangrene associated with heparin-induced thrombocytopenia. , 1985 .
[240] D. Henry,et al. Heparin‐induced thrombocytopenia: A prospective study , 1984, American journal of hematology.
[241] G. Martin,et al. Thrombocytopenia in a prospective, randomized, double-blind trial of bovine and porcine heparin. , 1984, The American journal of the medical sciences.
[242] R. Cipolle,et al. Heparin‐induced thrombocytopenia in patients with cerebrovascular ischemic disease , 1984, Neurology.
[243] G. Olinger,et al. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. , 1984, The Journal of thoracic and cardiovascular surgery.
[244] J. Kelton,et al. Studies on the frequency of heparin-associated thrombocytopenia. , 1984, Thrombosis research.
[245] D. Rosengarten,et al. Delayed‐onset heparin‐induced thrombocytopenia A potentially malignant syndrome , 1983, The Medical journal of Australia.
[246] R. Cipolle,et al. Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. , 1983, Therapeutic drug monitoring.
[247] George Mendelson,et al. Not “cured by a verdict” , 1982 .
[248] Heaton Dc,et al. Heparin induced thrombocytopenia: case reports and a prospective study. , 1982 .
[249] F. Cummings,et al. Effect of low-dose heparin on the platelet count. , 1982, Southern medical journal.
[250] J. Ansell,et al. Heparin Induced Thrombocytopenia: a Prospective Study , 1980, Thrombosis and Haemostasis.
[251] A. Gallus,et al. Heparin-associated thrombocytopenia: case report and prospective study. , 1980, Australian and New Zealand journal of medicine.
[252] J. Hirsh,et al. Thrombocytopenia found uncommonly during heparin therapy. , 1979, JAMA.
[253] U. Steinbrecher,et al. Heparin-associated thrombocytopenia: low frequency in 104 patients treated with heparin of intestinal mucosal origin. , 1979, Canadian Medical Association journal.
[254] J. Moake,et al. Heparin‐induced thrombocytopenia: Association with a platelet aggregating factor and arterial thromboses , 1979, American journal of hematology.
[255] B. Evatt,et al. In vitro studies of heparin-associated thrombocytopenia. , 1977, Thrombosis research.
[256] P. Tomasulo,et al. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. , 1976, Annals of internal medicine.
[257] R. B. Babcock,et al. Heparin-induced immune thrombocytopenia. , 1976, The New England journal of medicine.
[258] J. Bartholomew,et al. Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia in Elderly Patients , 2007, Drugs & aging.
[259] J. Harenberg. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. , 2007, Thrombosis research.
[260] P. Prandoni,et al. Heparin- induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin. A case report. , 2006, Haematologica.
[261] K. Raymondos,et al. Delivery of a healthy child 30 weeks after resuscitation for thromboembolism and treatment with danaparoid: 5-year follow up , 2006, Journal of perinatal medicine.
[262] T. Warkentin. Think of HIT. , 2006, Hematology. American Society of Hematology. Education Program.
[263] A. Greinacher,et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. , 2006, Thrombosis research.
[264] J. Kelton,et al. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. , 2005, Thrombosis research.
[265] M. Monreal,et al. Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia , 2004, European Journal of Clinical Pharmacology.
[266] J. Francis,et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. , 2003, The Annals of thoracic surgery.
[267] Z. Davis,et al. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. , 2003, The Annals of thoracic surgery.
[268] Maria Kotiou,et al. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. , 2002, The heart surgery forum.
[269] Delayed-onset heparin-induced thrombocytopenia and thrombosis. , 2001, Annals of internal medicine.
[270] G. Cuny,et al. Thrombopénie à l'héparine et filtre cave : difficultés du traitement , 1993 .